Litcius/Paper detail

Screening efficacy of available HIV protease inhibitors on COVID-19 protease

Mahmoud Mirzaei, Kun Harismah, Muhammad Da’i, Elham Salarrezaei, Zahra Roshandel

2020Majallah-i ṭibb-i niẓāmī28 citationsDOI

Abstract

Background and Aim: Advent of COVID-19 attracted the attentions of researchers to develop drugs for its treatment Besides efforts on developing new drugs, screening available drugs to see their efficacy on COVID-19 could be an urgent action of initiating its pharmacotherapy In this study, efficacy of HIV protease inhibitors on COVID-19 protease has been examined Methods: Molecular docking based screening by AutoDock software has been done to examine the efficacy of ligand-receptor interactions Results: Obtained results of binding energy, inhibitory constant and interactions quality have approved the idea of efficacy of HIV protease inhibitors on COVID-19 protease Conclusion: Quantitative results indicated different levels of efficacy of investigated ligands for inhibitory activity of COVID-19 and qualitative results indicated various localizations of ligands in the proposed active site of protease The concluding remarks of this study are to introduce Nelfinavir as the best ligand in quantitative respect and each of Saquinavir, Amprenavir and Fosamprenavir as the best ligands inqualitative respect for possible inhibitory effects on COVID-19 protease © 2020 Baqiyatallah University of Medical Sciences All rights reserved

Topics & Concepts

AmprenavirNelfinavirSaquinavirProteaseAutoDockProtease inhibitor (pharmacology)PharmacologyCoronavirus disease 2019 (COVID-19)MedicineDocking (animal)VirologyHuman immunodeficiency virus (HIV)HIV-1 proteaseChemistryEnzymeBiochemistryInfectious disease (medical specialty)Viral loadInternal medicineDiseaseAntiretroviral therapyNursingIn silicoGeneComputational Drug Discovery MethodsDiverse Scientific Research StudiesDrug-Induced Hepatotoxicity and Protection
Screening efficacy of available HIV protease inhibitors on COVID-19 protease | Litcius